Immatics N.V. (IMTX) Social Stream

Featured Post From StockTwits About IMTX

$IMTX Anyone with stocks in $CVAC $MRNA $ABCL or $LIFE is welcome to look at $IMTX.

Immatics publishes results for the second quarter of 2021 as well as an update on business development Patient recruitment for the ACTengine® studies continues to go according to plan; By the end of July, a total of 27 patients with various types of cancer had been treated with the product candidates IMA201, IMA202 or IMA203 Progress in the development of bispecific TCR molecules: IMA401 program on the way to clinical trial approval, publication of preclinical proof-of-concept data for the second TCER® program IMA402 On June 30, 2021, Immatics had cash and cash equivalents of 192.8 million euros (229.1 million US dollars1), which is expected to cover operating costs through 2023

https://www.globenewswire.com/news-release/2021/08/10/2277768/0/en/Immatics-Announces-Second-Quarter-2021-Financial-Results-and-Provides-Business-Update.html

What Else are IMTX Traders Talking About?

Other tickers frequently mentioned alongside IMTX are CVAC, MRNA, ABCL and LIFE.